IQInvest
Sign in

ABT

Abbott Laboratories

NYQ · Healthcare

$115.28

-$1.39 (-1.19%)down -1.19%

25 August 2026 · delayed 15+ min

F

Quality score52.1 / 100

Cut-offs are the grader's own: 97+ for an A+, below 60 is an F.

Abbott Laboratories earns a F on good profit margins (>10%) and positive free cash flow but high debt-to-equity ratio (>2.0) and negative earnings growth. Consider alternatives with better risk/reward profiles.

Model stance WEAK HOLD Suggested position 4.0% · $400.00 IQInvest estimate
Adjusted for Moderate investors, Medium-term investors 4.0% suggested allocation Change these

These change the suggested position size and the stance, not the category scores. Amount is in dollars.

IQ-ABT-20260825engine v1 · 7-category weighted scorecard

What it is worth, depending who you ask.

Today’s price against the year it has had and the targets analysts publish. Every marker is a reported figure, not a projection of ours.

52-week low

$81.97

Lowest analyst target

$103.00

Today's price

$115.28

Mean analyst target

$120.20

Highest analyst target

$135.00

52-week high

$137.49

ABT trades 60% of the way up its 52-week range, between $81.97 and $137.49. The mean analyst target of $120.20 is 4.3% above today's price.

Today’s price 52-week range Analyst price targets

Scored categories

Financial healthGood profit margins (>10%); Positive free cash flow; High debt-to-equity ratio (>2.0); Negative earnings growth 65.023%

Profit margin

11.65%

Net profit per unit of revenue

healthyWhat this means

Of every 100 units of revenue, this much survives as profit.

A comfortable buffer between revenue and costs.

Operating margin

14.71%

Before interest and tax

healthyWhat this means

Profit from operations, before interest and tax, per 100 of revenue.

The operations themselves are comfortably profitable.

Gross margin

56.85%

After the cost of goods only

highWhat this means

What is left of revenue after only the direct cost of the product.

Little marginal cost per sale, which is what lets software and pharma fund heavy R&D.

Return on equity

10.58%

Profit per unit of shareholder capital

strongWhat this means

Profit generated per unit of shareholder capital.

Above 15% is generally considered a good business.

Return on assets

5.33%

Profit per unit of assets

strongWhat this means

Profit generated per unit of everything the company owns.

The assets are working hard.

Debt to equity

63.21

Borrowings against equity

moderateWhat this means

Borrowings measured against shareholder capital.

Normal for most established companies.

Current ratio

1.38

Short-term assets over short-term debts

adequateWhat this means

Short-term assets against short-term obligations.

Enough to cover near-term bills.

Quick ratio

0.80

As above, excluding inventory

adequateWhat this means

Short-term assets excluding inventory, against short-term debts.

Near-term obligations are roughly covered without selling inventory.

Revenue growth

13.00%

Year on year

growingWhat this means

Change in revenue against the same period last year.

A healthy expansion rate.

Earnings growth

-47.50%

Year on year

fallingWhat this means

Change in earnings against the same period last year.

Profit is declining even if revenue is not.

Revenue

$11.16B

Trailing twelve months

Free cash flow

$7.21B

Cash left after capital spending

Operating cash flow

$9.91B

Cash from the business itself

Payout ratio

78.96%

Dividends as a share of earnings

highWhat this means

The share of earnings paid out as dividends.

Most of the profit goes out of the door, leaving less to reinvest.

Growth & momentumPoor 1-year return (-10.6%); Low Sharpe ratio (0.04) 30.022%

Return, 1 month

7.47%

Return, 3 months

35.51%

Return, 6 months

1.81%

Return, year to date

-5.45%

Return, 1 year

-10.56%

Return, 3 years

18.14%

Sharpe ratio

0.04

Return earned per unit of risk

modestWhat this means

Return earned per unit of risk taken.

Below 1 is the common case; return did not strongly outpace the volatility.

Win rate

50.64%

Share of days that closed up

about evenWhat this means

The share of trading days that closed higher.

Close to a coin flip, which is the norm — returns come from the size of moves, not their count.

Average daily return

0.01%

Best day

10.71%

Worst day

-10.04%

ValuationHigh P/E ratio (37.3) - may be overvalued; High PEG ratio (2.35) 15.018%

P/E ratio

37.31

Price against trailing earnings

highWhat this means

You pay 37.31 for every 1 unit of annual earnings.

Above about 25 the market is paying up for expected growth.

Forward P/E

19.01

Price against forecast earnings

moderateWhat this means

Price against next year's *forecast* earnings.

A conventional range.

PEG ratio

2.35

P/E adjusted for growth

expensive for the growthWhat this means

P/E divided by the growth rate — it asks whether the price is justified by the growth.

Above 2 you pay more per unit of growth than the convention treats as reasonable.

Price to book

3.90

Price against balance-sheet equity

well above bookWhat this means

Price against the accounting value of the company's net assets.

Normal for asset-light businesses, where the value sits in brands and software the balance sheet never records.

Price to sales

4.31

Price against revenue

highWhat this means

Price against revenue — usable when a company has no profit yet.

The price assumes today's revenue will convert into much more profit later.

EV / EBITDA

19.66

Whole-company value against cash earnings

highWhat this means

Whole-company value, debt included, against cash earnings.

Expensive even before interest, tax and depreciation are considered.

Enterprise value

$229.65B

Market value plus debt, minus cash — the price of the whole business

Shares outstanding

1,730,383,296

Shares the profit is split across

Dividend yield

2.16%

Annual dividend against price

meaningfulWhat this means

Annual dividend as a percentage of the share price.

A substantial part of the total return arrives as income.

TechnicalStrong trend (ADX > 25); MACD bullish (positive histogram); RSI overbought (>70) 100.015%

RSI (14)

71.8

Above 70 overbought, below 30 oversold

overboughtWhat this means

A 0–100 momentum gauge over the last 14 sessions.

Above 70 conventionally reads as overbought.

MACD

4.26

Momentum against its own trend

MACD histogram

0.15

Positive is bullish

ADX

38.9

Trend strength; above 25 is a real trend

trendingWhat this means

Trend strength, regardless of direction.

Above 25 is conventionally read as a genuine trend in force.

20-day average

$110.27

50-day average

$100.76

200-day average

$105.81

Price vs 50-day

14.41%

Price vs 200-day

8.96%

Bollinger upper

$117.52

Bollinger lower

$103.01

Average true range

2.50

Typical daily trading range

Stochastic %K

82.6

Risk4 measured figures 40.012%

Volatility, annualised

22.96%

How far it swings in a year

normalWhat this means

How far the price typically swings over a year.

A typical range for an individual share.

Beta

0.58

Moves against the wider market

steadier than the marketWhat this means

How much the price moves relative to the wider market.

Tends to move less than the index, in both directions.

Maximum drawdown

-39.64%

Worst peak-to-trough fall

significantWhat this means

The worst peak-to-trough fall in the period measured.

A serious decline, though not unusual over a multi-year window.

Risk category

Moderate

The engine's own banding

Analyst viewAnalyst consensus: Buy; Strong analyst coverage (25 analysts) 80.010%

Consensus

Buy

What covering analysts rate it

Analysts covering

25

Mean price target

$120.20

Highest target

$135.00

Lowest target

$103.00

Implied upside

4.26%

Target against today's price

limitedWhat this means

How far the mean analyst target sits above today's price.

Little headroom to the consensus target.

Price against the S&P 500

180 trading days to 2026-08-25

ABT is 6.1% down over the window, against 11.6% up for the S&P 500 — behind by 17.7 points.
ABT -6.1%S&P 500 +11.6%
Show the numbers
Sampled across the window. Both columns are rebased to 100 on 2025-12-05, so they can be compared directly.
DateCloseABT rebasedS&P 500 rebased
2025-12-05$122.80100.0100.0
2025-12-29$122.3099.6100.5
2026-01-21$119.1397.0100.1
2026-02-11$112.0891.3101.0
2026-03-05$109.5789.299.4
2026-03-26$103.1884.094.3
2026-04-17$96.1278.3103.7
2026-05-08$83.7268.2107.7
2026-06-01$87.1671.0110.6
2026-06-23$89.8973.2107.2
2026-07-15$89.2772.7110.2
2026-08-05$105.7186.1112.4

How the score was built

Each category is scored 0–100, then multiplied by its weight. The seven contributions sum to the quality score.
CategoryScoreWeightContribution
Financial health65.023%15.0
Growth & momentum30.022%6.6
Valuation15.018%2.7
Technical100.015%15.0
Risk40.012%4.8
Analyst view80.010%8.0
ESG50.00%0.0
Quality score100%52.0

ESG is scored but carries no weight in this grade. Add ?esg=1 to the address to include it — the engine then redistributes weight across the other six, so the whole scorecard changes, not just one row.

Argue with the model

Every other grader hands you a number. This one hands you the model.

Move a slider, press Recalculate, and the grade is rebuilt from the same category scores. Nothing is hidden: the scores are the engine's, only the weighting is yours.

18%
23%
22%
12%
15%
10%
0%

These are IQInvest's own weights, totalling 100%.

Your grade

F

52.0 / 100

Identical to the IQInvest grade.

All 66 metricsOne flat sortable table, for when you want everything at once.
Metric Category Value Source
Worst dayGrowth & momentum-10.04%Yahoo Finance
Win rateGrowth & momentum50.64%Yahoo Finance
VolumeMarket data1,841,874Yahoo Finance
Volatility, annualisedRisk22.96%Yahoo Finance
Stochastic %KTechnical82.6Yahoo Finance
Sharpe ratioGrowth & momentum0.04Yahoo Finance
Shares outstandingValuation1,730,383,296Yahoo Finance
RSI (14)Technical71.8Yahoo Finance
Risk categoryRiskModerateYahoo Finance
Revenue growthFinancial health13.00%Yahoo Finance
RevenueFinancial health$11.16BYahoo Finance
Return, year to dateGrowth & momentum-5.45%Yahoo Finance
Return, 6 monthsGrowth & momentum1.81%Yahoo Finance
Return, 3 yearsGrowth & momentum18.14%Yahoo Finance
Return, 3 monthsGrowth & momentum35.51%Yahoo Finance
Return, 1 yearGrowth & momentum-10.56%Yahoo Finance
Return, 1 monthGrowth & momentum7.47%Yahoo Finance
Return on equityFinancial health10.58%Yahoo Finance
Return on assetsFinancial health5.33%Yahoo Finance
Quick ratioFinancial health0.80Yahoo Finance
Profit marginFinancial health11.65%Yahoo Finance
Price vs 50-dayTechnical14.41%Yahoo Finance
Price vs 200-dayTechnical8.96%Yahoo Finance
Price to salesValuation4.31Yahoo Finance
Price to bookValuation3.90Yahoo Finance
Previous closeMarket data$116.67Yahoo Finance
PEG ratioValuation2.35Yahoo Finance
Payout ratioFinancial health78.96%Yahoo Finance
P/E ratioValuation37.31Yahoo Finance
Operating marginFinancial health14.71%Yahoo Finance
Operating cash flowFinancial health$9.91BYahoo Finance
OpenMarket data$115.83Yahoo Finance
Mean price targetAnalyst view$120.20Yahoo Finance
Maximum drawdownRisk-39.64%Yahoo Finance
MACD histogramTechnical0.15Yahoo Finance
MACDTechnical4.26Yahoo Finance
Lowest targetAnalyst view$103.00Yahoo Finance
Implied upsideAnalyst view4.26%Yahoo Finance
Highest targetAnalyst view$135.00Yahoo Finance
Gross marginFinancial health56.85%Yahoo Finance
Free cash flowFinancial health$7.21BYahoo Finance
Forward P/EValuation19.01Yahoo Finance
EV / EBITDAValuation19.66Yahoo Finance
Enterprise valueValuation$229.65BYahoo Finance
EmployeesMarket data122,000Yahoo Finance
Earnings growthFinancial health-47.50%Yahoo Finance
Dividend yieldValuation2.16%Yahoo Finance
Debt to equityFinancial health63.21Yahoo Finance
Day lowMarket data$115.03Yahoo Finance
Day highMarket data$116.61Yahoo Finance
Current ratioFinancial health1.38Yahoo Finance
ConsensusAnalyst viewBuyYahoo Finance
Bollinger upperTechnical$117.52Yahoo Finance
Bollinger lowerTechnical$103.01Yahoo Finance
BetaRisk0.58Yahoo Finance
Best dayGrowth & momentum10.71%Yahoo Finance
Average volumeMarket data11,875,911Yahoo Finance
Average true rangeTechnical2.50Yahoo Finance
Average daily returnGrowth & momentum0.01%Yahoo Finance
Analysts coveringAnalyst view25Yahoo Finance
ADXTechnical38.9Yahoo Finance
52-week lowMarket data$81.97Yahoo Finance
52-week highMarket data$137.49Yahoo Finance
50-day averageTechnical$100.76Yahoo Finance
200-day averageTechnical$105.81Yahoo Finance
20-day averageTechnical$110.27Yahoo Finance
Add to portfolio Compare Peers Set a price target

Yahoo Finance via yfinance · delayed 15 minutes or more